SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila receives nod from USFDA for Fingolimod Capsules

15 Jul 2017 Evaluate

Zydus Cadila has received the tentative approval from the United States Food & Drug Administration (USFDA) to market Fingolimod Capsules 0.5 mg, mainly used for treatment of multiple sclerosis. The drug will be produced at the group's formulations manufacturing facility at the pharma SEZ, in Ahmedabad. The estimated sales for Fingolimod Capsules is $2.1 billion, as per IMS MAT May 2017.

The group now has over 120 approvals and has so far filed more than 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

942.55 0.00 (0.00%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×